{"id":"azasite-eye-drops","safety":{"commonSideEffects":[{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Ocular discomfort"},{"rate":null,"effect":"Blurred vision"}]},"_chembl":{"chemblId":"CHEMBL5940488","moleculeType":null,"molecularWeight":"498.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. In addition to its antimicrobial activity, azithromycin has anti-inflammatory properties that help reduce ocular surface inflammation and improve tear film stability, making it effective for both infectious and inflammatory ocular conditions.","oneSentence":"AzaSite is an azithromycin ophthalmic suspension that reduces bacterial load and inflammatory mediators in the eye to treat bacterial conjunctivitis and meibomian gland dysfunction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:56.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Meibomian gland dysfunction (dry eye disease)"}]},"trialDetails":[{"nctId":"NCT03162497","phase":"PHASE4","title":"Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2018-01-08","conditions":"Dry Eye Syndromes, Meibomian Gland Dysfunction","enrollment":23},{"nctId":"NCT06921525","phase":"PHASE1, PHASE2","title":"Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Ehab Mohamed Elsayed Mohamed Saad","startDate":"2025-04-01","conditions":"Dry Eye","enrollment":44},{"nctId":"NCT01408082","phase":"PHASE3","title":"Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2011-10","conditions":"Blepharitis","enrollment":917},{"nctId":"NCT01560962","phase":"NA","title":"Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis","status":"TERMINATED","sponsor":"Southern California Institute for Research and Education","startDate":"2012-01","conditions":"Blepharitis","enrollment":100},{"nctId":"NCT03252067","phase":"PHASE1","title":"Tear Concentrations and Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2017-08-02","conditions":"Pharmacokinetics","enrollment":42},{"nctId":"NCT03235141","phase":"PHASE1","title":"Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2017-07-07","conditions":"Bacterial Conjunctivitis","enrollment":56},{"nctId":"NCT01797107","phase":"PHASE2","title":"Study to Determine the Effect of Azasite on Corneal Surface Irregularity","status":"WITHDRAWN","sponsor":"Philadelphia Eye Associates","startDate":"2013-03","conditions":"Meibomian Gland Dysfunction","enrollment":""},{"nctId":"NCT01721694","phase":"PHASE3","title":"Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection","status":"WITHDRAWN","sponsor":"Adapt Produtos Oftalmológicos Ltda.","startDate":"2012-12","conditions":"Ocular Inflammation, Infection Associated Blepharitis, Keratitis","enrollment":""},{"nctId":"NCT01089608","phase":"PHASE2","title":"Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2010-03","conditions":"Blepharitis","enrollment":93},{"nctId":"NCT01220258","phase":"PHASE2","title":"A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11","conditions":"Posterior Blepharoconjunctivitis","enrollment":29},{"nctId":"NCT00105469","phase":"PHASE3","title":"Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-07","conditions":"Bacterial Conjunctivitis","enrollment":743},{"nctId":"NCT00105534","phase":"PHASE3","title":"Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-07","conditions":"Bacterial Conjunctivitis","enrollment":685},{"nctId":"NCT01269658","phase":"PHASE2","title":"A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-12","conditions":"Blepharitis","enrollment":40},{"nctId":"NCT00894530","phase":"PHASE2","title":"The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-05","conditions":"Blepharitis","enrollment":314},{"nctId":"NCT01102244","phase":"PHASE3","title":"A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-04","conditions":"Blepharitis","enrollment":122},{"nctId":"NCT00656539","phase":"PHASE4","title":"Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04","conditions":"Blepharitis","enrollment":20},{"nctId":"NCT00629941","phase":"PHASE4","title":"Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Blepharitis","enrollment":25},{"nctId":"NCT01014078","phase":"PHASE4","title":"A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10","conditions":"Dry Eye Disease","enrollment":112},{"nctId":"NCT00629980","phase":"PHASE4","title":"Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Blepharitis","enrollment":60},{"nctId":"NCT00892970","phase":"PHASE2","title":"The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Blepharitis","enrollment":313},{"nctId":"NCT00629590","phase":"PHASE4","title":"Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Blepharitis","enrollment":20},{"nctId":"NCT01105624","phase":"PHASE4","title":"A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-03","conditions":"Contact Lens Dry Eye","enrollment":50},{"nctId":"NCT00564447","phase":"PHASE4","title":"Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Bacterial Infections, Eye Infections","enrollment":48},{"nctId":"NCT00575380","phase":"PHASE4","title":"Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Bacterial Infections, Eye Infections, Cataract Extraction","enrollment":116},{"nctId":"NCT00575367","phase":"PHASE4","title":"Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Bacterial Infections, Eye Infections","enrollment":37},{"nctId":"NCT00357773","phase":"PHASE3","title":"Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2004-05","conditions":"Conjunctivitis, Bacterial","enrollment":""},{"nctId":"NCT00357539","phase":"PHASE1","title":"Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2002-02","conditions":"Eye Infections, Bacterial","enrollment":""},{"nctId":"NCT00357292","phase":"PHASE1","title":"Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2002-03","conditions":"Eye Infections, Bacterial","enrollment":""},{"nctId":"NCT00357383","phase":"PHASE1","title":"Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2002-10","conditions":"Eye Infections, Bacterial","enrollment":""},{"nctId":"NCT00356772","phase":"PHASE1","title":"Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2003-02","conditions":"Eye Infections, Bacterial","enrollment":""},{"nctId":"NCT00356720","phase":"PHASE3","title":"Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2004-01","conditions":"Trachoma","enrollment":""},{"nctId":"NCT00356850","phase":"PHASE1","title":"Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2002-05","conditions":"Eye Infections, Bacterial","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AzaSite (azithromycin ophthalmic solution)"],"phase":"marketed","status":"active","brandName":"AzaSite Eye Drops","genericName":"AzaSite Eye Drops","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AzaSite is an azithromycin ophthalmic suspension that reduces bacterial load and inflammatory mediators in the eye to treat bacterial conjunctivitis and meibomian gland dysfunction. Used for Bacterial conjunctivitis, Meibomian gland dysfunction (dry eye disease).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}